Skip to main content

Table 1 Main characteristics of studies included in the meta-analysis

From: Clinicohistopathological implications of MMP/VEGF expression in retinoblastoma: a combined meta-analysis and bioinformatics analysis

Study Country Inclusion period Number of patients Gender Eye Age Clinical staging Tumor invasion Histological type Preoperative treatment Detection method Expression evaluation standards MMP types NOS score
Male/female Right/left /II+III N0/NX Well + moderately/poorly diff
Yun Li et al. (2006) China 1996–2005 30 18/12 NA Range 4 month–6 years
Median 2.9 years
13/17 17/13 11/19 NA IHC Proportion MMP-1
MMP-9
8
Haiyan Li et al. (2012) China 2002–2011 52 31/21 33/29 Range 6 month–9 years
Mean 5.1 ± 1.2 years
NA 28/24 24/28 No chemo IHC Proportion + intensity MMP-1
MMP-9
VEGF
7
Siqi Yuan et al. (2010) China 2000–2009 31 23/18 NA Range 5 month–9 years
Median 3.3 years
NA 17/14 13/18 NA IHC Proportion + intensity MMP-1
VEGF
6
Mohan Adithi et al. (2006) India 2000–2003 55 35/20 29/26 Range 1 month–14 years
Median 2 years
0/55 23/32 21/34 No chemo IHC Proportion MMP-2
MMP-9
8
Yang Yang et al. (2013) China 2001–2012 45 23/22 24/21 Range 2 month–8 years 36/9 26/19 17/28 No chemo
No radio
IHC Proportion MMP-2 6
Lin Zhou et al. (2010) China 1989–2010 40 23/17 17/23 Range 4 month–18 years
Median 2.9 years
NA 27/13 15/25 No chemo
No radio
IHC Proportion + intensity MMP-2
MMP-9
VEGF
6
Jun Liang et al. (2017) China 2011–2016 100 66/34 NA Range 4 month–11 years
Median 4.2 years
39/61 NA 55/45 NA IHC Proportion + intensity MMP-9
VEGF
8
Yan Sun et al. (2014) China 2000–2011 56 29/27 NA Range 3 month–7 years
Mean 3.6 years
20/16 28/28 31/25 No chemo IHC Proportion + intensity MMP-9 7
Zhen Ge et al. (2007) China 1995–2005 32 19/13 NA Range 4 month–10 years
Median 3.1 years
NA 21/11 12/20 No chemo IHC Proportion + intensity MMP-9
VEGF
6
Zixu Wu et al. (2011) China 2000–2010 41 23/18 NA NA 29/12 24/17 20/21 NA IHC Proportion + intensity MMP-9 6
Jia Yu et al. (2009) China 1990–2006 47 25/12 20/27 Range 6 month–10 years NA 32/15 17/30 No chemo
No radio
IHC Proportion + intensity MMP-9
VEGF
6
Yuejun Liu et al. (2014) China 2010–2014 30 18/12 NA Mean 5.2 years NA 17/13 12/18 No chemo IHC Proportion + intensity MMP-9 6
Ying Jiang et al. (2004) China 1999–2002 22 NA NA Range 2 month–5 years
Mean 2.4 years
NA 14/8 8/14 No chemo
No radio
IHC Proportion VEGF 7
Nermeen S Youssef et al. (2014) Egypt 2009–2013 56 24/32 23/40 Mean 20.94 m ± 11.75 months NA 26/30 36/20 No preoperative adjunctive treatments IHC percentage VEGF 8
Lijuan Meng et al. (2011) China NA 48 27/21 22/26 Range 5 month–8y NA 21/27 19/29 No chemo
No radio
IHC Proportion × intensity MMP-9
VEGF
6
Li Fang et al. (2010) China 2000–2007 33 18/15 14/19 Range 6 month–9 years NA 22/11 12/21 No chemo
No radio
IHC Proportion + intensity VEGF 6
  1. m month, y year, IHC immunohistochemistry, NA not available, chemo chemotherapy, radi radiation therapy, diff differentiation, N0: absent local invasion, Nx optic nerve, optic nerve, choroidal, or scleral invasion, Proportion percentage of positive cells, intensity staining intensity of positive cells